EVALUATION OF DNA REPAIR FUNCTION AS A PREDICTOR OF RESPONSE IN A CLINICAL TRIAL OF PARP INHIBITOR MONOTHERAPY FOR RECURRENT OVARIAN CARCINOMA
$357,648FY2013Department of DefenseDOD
Mayo Clinic, Rochester MN
Investigators
View source on USAspending →EVALUATION OF DNA REPAIR FUNCTION AS A PREDICTOR OF RESPONSE IN A CLINICAL TRIAL OF PARP INHIBITOR MONOTHERAPY FOR RECURRENT OVARIAN CARCINOMA · GrantIndex